ライフサイエンスコーパス: WT1 protein

1 Par-4 and an induction in the expression of WT1 protein.

2 sence of a 17-amino-acid sequence within the WT1 protein.

3 peptides and antibody responses specific for WT1 protein.

4 vealed that this gel shift complex contained WT1 protein.

5 wild-type and tumor-derived missense mutant WT1 proteins.

6 shion, implying a gain of function by mutant WT1 proteins.

7 ociated with WT1 variants and shows that the WT1 protein affecting ZF4 can function as a protestis fa

8 Both events result in a functionally changed WT1 protein and are potential mechanisms of altering nor

9 overexpression of miR-466o-3p downregulated WT1 protein and promoted podocyte injury in vitro.

10 several oncogenic proteins, associates with WT1 protein and stabilizes its expression.

11 High levels of the Wilms' Tumor 1 (WT1) protein and mRNA had been associated with aggressiv

12 Finally, we detected Par-4 and WT1 proteins binding to a previously identified WT1-bind

13 The WT1 protein binds to the promoters of many genes through

14 Furthermore, WT1 protein bound to specific DNA-binding sites located

15 Two recombinant WT1 proteins containing the DNA binding domain with or w

16 To determine whether the WT1 protein continued to be processed and presented in t

17 ern blot and FACS analysis which showed that WT1 protein expression was highest in S phase and almost

18 Our data strongly suggest that mutant WT1 proteins facilitate expression of these cell cycle g

19 findings show for the first time that mutant WT1 proteins have a gain-of-function and act as oncogene

20 Immunofluorescent staining of the WT1 protein in 3T3 and 293 cell clones, stably transfect

21 Aoc1 mRNA levels correlated with WT1 protein in several cell lines.

22 tected endogenous expression of Wt1 mRNA and Wt1 protein in the proepicardium and epicardium and also

23 rected against the N-terminus portion of the WT1 protein in the sera of 3 of 18 patients with acute m

24 Mutant WT1 proteins in Denys-Drash syndrome patients were unabl

25 We also expressed wild-type and mutant WT1 proteins in human mesenchymal stem cells and establi

26 The WT1 protein is normally expressed in the developing geni

27 Although WT1 protein is predominantly localized to the nucleus, t

28 Decreased expression of WT1 protein led to cell cycle arrest at the G1 phase and

29 mab (Herceptintrade mark) antibody decreased WT1 protein levels in HER2/neu-overexpressing BT-474 and

30 e to healthy controls and non-trisomy 8 MDS; WT1 protein levels were also significantly elevated.

31 tutional WT1 mutations that encode truncated WT1 proteins may predispose to the development of crypto

32 ity in malignancies known to overexpress the WT1 protein, particularly glioblastoma, and provide a ra

33 ges Akt to increase WT1 expression, and that WT1 protein plays a vital role in regulating cell cycle

34 WT1 mRNA may regulate gene targeting of the WT1 protein through changes either in its regulatory or

35 Binding of WT1 protein to a cis-regulatory element in the AOC1 prom

36 Binding of Wt1 protein to these elements was verified by EMSA and C

37 Antisense inhibition of WT1 protein translation strongly reduced Aoc1 transcript

38 Concordant with the other findings, WT1 protein was increased in juvenile DM muscle, with av

39 A significant decrease in total WT1 protein was observed by both immunocytochemistry and

40 Contrary to previous reports, WT1 protein was strongly expressed in primary carcinomas

41 To investigate the function of mutant WT1 proteins, we performed WT1 knockdown experiments in

42 Approximately threefold higher levels of WT1 protein were observed in MCF-7 breast cancer cells t

43 All are predicted to produce a truncated WT1 protein with absence or disruption of the zinc finge

44 nt to restore the functional properties of a WT1 protein with an amino-terminal deletion, an effect t

45 Here, we show that the WT1 protein with and without the KTS tripeptide can repr